Aardvark Therapeutics, Inc. (NasdaqGS: AARD)
Health Care · Pharmaceuticals · US
$7.25
+5.38% today · -19.8% 1Y
Aardvark Therapeutics, Inc. (NasdaqGS: AARD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $158.67M and employs 28 people.
Over the last twelve months the share price has lost 19.8%, trading between 3.35 and 17.94.
Tweenvest scores Aardvark Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
AARD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $158.67M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.20
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $17.94
- 52-week low
- $3.35
- Avg volume (3M)
- —
- Shares outstanding
- 21.88M
- Employees
- 28
- Next earnings
- —
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
- ISIN
- US0029421007
- Founded
- 2017
- Listed since
- Feb 13, 2025
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,231.11 | -0.21% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.15 | +0.00% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.16 | -0.19% |
| Roche Holding AGSWX: ROP | $371.62B | CHF371.90 | -0.51% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.29 | -1.18% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.